Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group

6 Feb 2013 11:18

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

PR Newswire

London, February 6

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, on

dealings are being disclosed: behalf of discretionary clients. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to Ark Therapeutics Group plc whose relevant securities this form relates: Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 05 February 2013 (f) Has the discloser previously disclosed, or Y/N NO are they today disclosing, under the Code in respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number % (1) Relevant securities owned 28,860,092 13.79 0 0.0 and/or controlled: (2) Derivatives (other than options): (3) Options and agreements to purchase/sell: TOTAL: 28,860,092 13.79 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/A relation to which subscription right exists: Details, including nature of the N/A rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 2,915,000 1.009p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price

date money security e.g. call selling, to which per unit e.g.

paid/

option varying option American, received etc. relates European per unit etc. N/A (ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or

understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person

making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none" None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,

between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 06 February 2013 Contact name: David Holland, for Aberforth Partners LLP Telephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
Date   Source Headline
22nd Apr 20093:34 pmRNSAGM Results
7th Apr 200911:09 amRNSAnnual Information Update
7th Apr 20097:00 amRNSResearch Update
17th Mar 20095:03 pmRNSHolding(s) in Company
13th Mar 20094:25 pmRNSHolding(s) in Company
11th Mar 20097:00 amRNSFinal Results
2nd Mar 200911:21 amRNSVoting Rights and Capital
26th Feb 20097:00 amRNSPatent Filing
17th Feb 20092:14 pmRNSHolding(s) in Company
16th Feb 20095:39 pmRNSHolding(s) in Company
16th Feb 20097:00 amRNSResearch Update
5th Feb 200910:50 amRNSDealing by Employee Benefit Trust
2nd Feb 20097:00 amRNSDirector/PDMR Shareholding
21st Jan 20094:40 pmRNSSecond Price Monitoring Extn
21st Jan 20094:37 pmRNSPrice Monitoring Extension
21st Jan 200912:12 pmRNSNotice of Results
14th Jan 20097:00 amRNSRe Agreement
9th Jan 200910:23 amRNSHolding(s) in Company
8th Jan 20097:00 amRNSTrinam Phase III trial to commence
6th Jan 20097:00 amRNSResearch Update
31st Dec 20089:00 amRNSTotal Voting Rights
16th Dec 20083:46 pmRNSNotification of Major Interests in Shares
9th Dec 20084:40 pmRNSSecond Price Monitoring Extn
9th Dec 20084:35 pmRNSPrice Monitoring Extension
9th Dec 20087:00 amRNSRegulatory Approval
5th Dec 20082:28 pmRNSBlocklisting Six Monthly Return
1st Dec 20087:00 amRNSRegulatory Application
24th Nov 200811:58 amRNSDirector/PDMR Shareholding
13th Nov 20087:00 amRNSInterim Management Statement
20th Oct 20087:00 amRNSProduct Launch
2nd Oct 20087:00 amRNSArk secures reimbursement for Neuropad
30th Sep 20085:06 pmRNSVoting Rights and Capital
17th Sep 20081:08 pmRNSHolding(s) in Company
27th Aug 20087:00 amRNSInterim Results
27th Aug 20087:00 amRNSResearch Update
26th Aug 20084:08 pmRNSHolding(s) in Company
1st Aug 200810:47 amRNSVoting Rights and Captial
31st Jul 20081:12 pmRNSHolding(s) in Company
30th Jul 20087:00 amRNSResearch Update
16th Jul 20087:00 amRNSResearch Update
8th Jul 200811:00 amRNSArk opens new manufacturing f
24th Jun 200811:28 amRNSHolding(s) in Company
18th Jun 20087:00 amRNSResearch Update
6th Jun 200812:10 pmRNSBlocklisting Application
3rd Jun 200810:58 amRNSBlocklisting Interim Review
3rd Jun 200810:51 amRNSBlocklisting Interim Review
2nd Jun 20087:00 amRNSRegulatory Approval
30th May 20084:52 pmRNSVoting Rights and Capital
30th May 20087:00 amRNSResearch Update
22nd May 20081:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.